EpiVax Demonstrates Antigen-Specific Tolerance Induction in Allergy with Tregitopes, Results Published in Frontiers in Immunology
PR89216
PROVIDENCE, R.I., April 27, 2021 /PRNewswire=KYODO JBN/ --
EpiVax, Inc. ("EpiVax") announces the publication "Tregitopes Improve Asthma by
Promoting Highly Suppressive and Antigen-Specific Tregs" in Frontiers in
Immunology (
). This research highlights Tregitopes as a promising therapy for allergy.
Administration of IgG-derived Tregitopes were found to induce suppressive
antigen-specific T-regulatory cells in ovalbumin (OVA) and ragweed-allergic
murine mouse models, attenuating allergen-induced airway hyperresponsiveness
and lung inflammation.
Logo - https://mma.prnewswire.com/media/542055/EpiVax_Logo.jpg
Tregitopes are peptides found in human immunoglobulin which were first
discovered in 2008 by Dr. Anne De Groot and William Martin. EpiVax has since
validated many more Tregitopes and has developed a strong Tregitope patent
estate. With a wide range of therapeutic applications, Tregitopes can be
co-formulated or fused to proteins to induce antigen-specific tolerance. EpiVax
is currently licensing Tregitope with commercial and academic partners. More
information on the EpiVax Tregitope Platform is available here (
).
Tregitopes are capable of engaging regulatory T cells and downregulating
inflammation in a wide range of disease models. This mechanism of action has
been used by others seeking to harness the value of Tregitopes, including
Marieme Dembele, Dr. Bruce Mazer and Amir Massoud of McGill University,
Montreal, Canada. Dembele and team previously demonstrated antigen specific
tolerance induction by Tregitopes in allergic airways disease. Tregitope-driven
antigen-specific down-regulation has been documented in other disease models,
including Type I diabetes (
More%20information%20on%20the%20EpiVax%20Tregitope%20Platform%20is%20available%2
0here%20(%20https:/c212.net/c/link/?t=0&l=en&o=3142107-1&h=3949850982&u=https%3A
%2F%2Fepivax.com%2Fpipeline%2Ftregitope-immunomodulation-power-tool&a=More+infor
mation+on+the+EpiVax+Tregitope+Platform+is+available+here.%20). ), cockroach
induced-allergy (
), experimental colitis (
), and pregnancy loss (
). EpiVax is encouraged by these findings and looks forward to a continued
bright future for the Tregitope program.
On the potential for future therapies, Dr. Bruce Mazer, Senior Scientist at The
Research Institute of The McGill University Health Centre said,
"Tregitope-based therapy may lead to improved treatments for allergy and other
inflammatory conditions. IgG Tregitope-based treatment could become a synthetic
alternative to IVIg, with more specificity and likely less side effects unlike
steroid-based immunosuppressant treatments for allergic asthma."
About EpiVax:
EpiVax is a biotechnology company with expertise in T cell epitope prediction,
immune modulation, and rapid vaccine design. EpiVax's immunogenicity screening
toolkits for therapeutics and vaccines, ISPRI and iVAX, are employed in
advancing the research of a global roster of companies.
For more information about EpiVax, visit www.epivax.com.
For more information on Tregitope and licensing opportunities please contact us
here ( https://epivax.com/about-us/contact-us ).
For a free online version of this published research visit Frontiers in
Immunology here (
).
Press Contact:
Katie Porter, Business Development Manager
EpiVax
kporter@epivax.com
SOURCE EpiVax Inc.
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。
